Biology Reference
In-Depth Information
Jones KD (1999) The importance of hemoglobin levels during radiotherapy for carcinoma of the
cervix.
Cancer
86: 1528-1536
97 Stadler P, Becker A, Feldmann HJ, Hansgen G, Dunst J, Wurschmidt F, Molls M (1999) Influence
of the hypoxic subvolume on the survival of patients with head and neck cancer.
Int J Radiat
Oncol Biol Phys
44: 749-754
98 Becker A, Stadler P, Lavey RS, Hansgen G, Kuhnt T, Lautenschlager C, Feldmann HJ, Molls M,
Dunst J (2000) Severe anemia is associated with poor tumor oxygenation in head and neck squa-
mous cell carcinomas.
Int J Radiat Oncol Biol Phys
46: 459-466
99 Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW, Mueller-Klieser W
(2001) Elevated tumor lactate concentrations predict for an increased risk of metastases in head-
and-neck cancer
. Int J Radiat Oncol Biol Phys
51: 349-353
100 Glaser CM, Millesi W, Kornek GV, Lang S, Schull B, Watzinger F, Selzer E, Lavey RS (2001)
Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative
chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx.
Int J
Radiat Oncol Biol Phys
50:705-715
101 Teicher BA, Holden SA, al-Achi A, Herman TS (1990) Classification of antineoplastic treatments
by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations
in
vivo
in the FSaIIC murine fibrosarcoma.
Cancer Res
50: 3339-3344
102 Thews O, Kelleher DK, Vaupel P (1996)
In vivo
oxygen consumption rate of DS sarcoma cells
on inhibition of DNA synthesis.
Cancer Res
56: 2009-2012
103 Jiang BH, Agani F, Passaniti A, Semenza GL (1997) V-SRC induces expression of hypoxia-
inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth fac-
tor and enolase 1: Involvement of HIF-1 in tumor progression.
Cancer Res
57: 5328-5335
104 Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB,
Semenza GL, Simons JW (1999) Overexpression of hypoxia-inducible factor 1alpha in common
human cancers and their metastases.
Cancer Res
59: 5830-5835
105 Semenza GL (2000) Hypoxia, clonal selection, and the role of HIF-1 in tumor progression.
Crit
Rev Biochem Mol Biol
35: 71-103
106 Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza
GL (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth
factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells:
Implications for tumor angiogenesis and therapeutics.
Cancer Res
60:1541-1545
107 Laughner E, Taghavi P, C hiles K, Mahon PC, Semenza GL (2001) HER2 (neu) signaling increas-
es the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for
HIF-1-mediated vascular endothelial growth factor expression.
Mol Cell Biol
21: 3995-4004
108 Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL (2002) Insulin-like growth factor 1
induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression,
which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer
cells.
J Biol Chem
277: 38205-38211
109 Semenza GL (2002) Involvement of hypoxia-inducible factor 1 in human cancer.
Intern Med
41:
79-83
110 Dancey J, Zee B, Osoba D, Whitehead M, Lu F, Kaizer L, Latreille J, Pater JL (1997) Quality of
life scores: An independent prognostic variable in a general population of cancer patients receiv-
ing chemotherapy. The National Cancer Institute of Canada Clinical Trials Group.
Qual Life Res
6:151-158
111 Littlewood TJ (2001) The impact of hemoglobin levels on treatment outcomes in patients with
cancer.
Semin Oncol
28: 49-53
112 Jumbe NL (2002) Erythropoietic agents as neurotherapeutic agents: What barriers exist?
Oncology (Huntingt)
16: 91-107
113 Brines M (2002) What evidence supports use of erythropoietin as a novel neurotherapeutic?
Oncology (Huntingt)
16:79-89
114 Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A
(2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury.
Proc Natl Acad Sci USA
97: 10526-10531
115 Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF (2000) Cognitive function in
breast cancer patients receiving adjuvant chemotherapy.
J Clin Oncol
18: 2695-2701
